Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida
Gorde:
| Egile nagusia: | |
|---|---|
| Argitaratze data: | 2015 |
| Formatua: | Doctoral thesis |
| Hizkuntza: | por |
| Baliabidea: | Repositório Institucional da UFG |
| Download full: | http://repositorio.bc.ufg.br/tede/handle/tede/5408 |
Gaia: | Controlled ovarian stimulation has become an integral part of infertility treatment. Treatment options with recombinant gonadotrophins add more to knowledge on folliculogenesis and ovarian steroidogenesis. The role of recombinant luteinizing hormone is controversial undergoing ovarian stimulation and has been widely debated. Objective: To compare the effects of supplementation with recombinant luteinizing hormone (rLH) for controlled ovarian stimulation with recombinant follicle stimulating hormone (rFSH) in a protocol with GnRH-antagonist in cycles of IVF/ICSI. Methods: Case-control study with 113 patients attended at a university center in the city of Goiania, aged between 34-42 years, who were divided into two groups according to an ovarian stimulation scheme: Group I (n= 60): rFSH (control group) and Group II (n= 53): rFSH + rLH (treated group). These groups were comparable for age, BMI, duration of infertility, serum FSH, LH and estradiol. Numbers of oocytes collected and in metaphase II, fertilization rate, embryos rate and rates of chemical and clinical pregnancy were analyzed. Data analysis was conducted using the statistical software BioStat ® 5.3. Differences in proportions were assessed by chi-square test and means by Wilcoxon Mann- Whitney test. P < 0,05 was considered statistically significant. Results: The mean age of patients in Group I was 37.3±2.1 years and Group II 37.9±2.4 years (P > 0.05). The comparability of the other main characteristics (duration of infertility, BMI, FSH, LH and basal estradiol) were also observed between Groups I and II (P > 0.05). There was no significant difference between the two groups regarding: number of oocytes retrieved (Group I= 4.9 ± 2.1, Group II= 5.7 ± 2.6, P= 0.061), number of oocytes in metaphase II (Group I= 3.4 ± 1.6, Group II= 4.0 ± 1.9, P= 0.060), fertilization rate (Group I= 65.3%, Group II= 69.4 %, OR 1.20, 95% CI 0.85-1.70, P= 0.282), embryos rate (Group I= 85.4%, Group II= 88.5%, OR 1.31, 95% CI 0.73-2.36, P= 0.355), rate of chemical pregnancy (Group I= 20.0%, Group II= 24.5%; OR 1.30, 95% CI 0.53-3.16, P= 0.562) and clinical pregnancy rate (Group I= 20.0%, Group II= 22.6%, OR 1.17, 95% CI 0.47-2.89, P= 0.731). Conclusion: In this study it was concluded that supplementation with r-LH showed no benefit with respect to variables during controlled ovarian stimulation with GnRH antagonists. |
| _version_ | 1871426375803469824 |
|---|---|
| author | Maia, Mônica Canêdo Silva |
| author_browse | Maia, Mônica Canêdo Silva |
| author_facet | Maia, Mônica Canêdo Silva |
| author_role | author |
| bitstream.checksum.fl_str_mv | bd3efa91386c1718a7f26a329fdcb468 4afdbb8c545fd630ea7db775da747b2f ef48816a10f2d45f2e2fee2f478e2faf 9da0b6dfac957114c6a7714714b86306 b52ab9d3f319bc193309f78f9ef2e243 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://repositorio.bc.ufg.br/tede/bitstreams/28250bbb-3f61-445b-bd42-9c769c168e2c/download http://repositorio.bc.ufg.br/tede/bitstreams/32bd894b-1d4a-4bce-9317-720756b7fa7d/download http://repositorio.bc.ufg.br/tede/bitstreams/f2adccdb-9a8c-47fa-ab15-418c3f5cc957/download http://repositorio.bc.ufg.br/tede/bitstreams/98b32863-04be-4f0a-8a0d-f8723a2fda8c/download http://repositorio.bc.ufg.br/tede/bitstreams/c9b62c93-2fa0-458b-ab40-e60d2a7f7f0a/download |
| collection | Repositório Institucional da UFG |
| contributor_str_mv | Approbato, Mário Silva Approbato, Mário Silva Sanchez, Eliane Gouveia de Morais Siriano, Liliane da Rocha Barbosa, Maria Alves Guimarães, Valeriana de Castro |
| dc.contributor.advisor1.fl_str_mv | Approbato, Mário Silva |
| dc.contributor.advisor1Lattes.fl_str_mv | http://lattes.cnpq.br/3408700658976397 |
| dc.contributor.author.fl_str_mv | Maia, Mônica Canêdo Silva |
| dc.contributor.authorLattes.fl_str_mv | http://lattes.cnpq.br/8921727225719363 |
| dc.contributor.referee1.fl_str_mv | Approbato, Mário Silva |
| dc.contributor.referee2.fl_str_mv | Sanchez, Eliane Gouveia de Morais |
| dc.contributor.referee3.fl_str_mv | Siriano, Liliane da Rocha |
| dc.contributor.referee4.fl_str_mv | Barbosa, Maria Alves |
| dc.contributor.referee5.fl_str_mv | Guimarães, Valeriana de Castro |
| dc.date.accessioned.fl_str_mv | 2016-04-04T11:56:43Z |
| dc.date.issued.fl_str_mv | 2015-12-03 |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.citation.fl_str_mv | MAIA, M. C. S. Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida. 2015. 101 f. Tese (Doutorado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2015. |
| dc.identifier.uri.fl_str_mv | http://repositorio.bc.ufg.br/tede/handle/tede/5408 |
| dc.language.iso.fl_str_mv | por |
| dc.publisher.country.fl_str_mv | Brasil |
| dc.publisher.department.fl_str_mv | Faculdade de Medicina - FM (RG) |
| dc.publisher.initials.fl_str_mv | UFG |
| dc.publisher.none.fl_str_mv | Universidade Federal de Goiás |
| dc.publisher.program.fl_str_mv | Programa de Pós-graduação em Ciências da Saúde (FM) |
| dc.relation.cnpq.fl_str_mv | -969369452308786627 |
| dc.relation.confidence.fl_str_mv | 600 600 600 |
| dc.relation.department.fl_str_mv | 1545772475950486338 |
| dc.relation.program.fl_str_mv | -1006864312617745310 |
| dc.rights.driver.fl_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:Repositório Institucional da UFG instname:Universidade Federal de Goiás (UFG) instacron:UFG |
| dc.subject.cnpq.fl_str_mv | CIENCIAS DA SAUDE::MEDICINA |
| dc.subject.eng.fl_str_mv | Ovarian stimulation In vitro fertilization Recombinant luteinizing hormone Supplementation LH |
| dc.subject.por.fl_str_mv | Estimulação ovariana Fertilização in vitro Hormônio luteinizante recombinante Suplementação com LH |
| dc.title.alternative.eng.fl_str_mv | Use of recombinant luteinizing hormone in assisted reproduction cycles |
| dc.title.por.fl_str_mv | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| dc.type.driver.fl_str_mv | info:eu-repo/semantics/doctoralThesis |
| dc.type.status.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Controlled ovarian stimulation has become an integral part of infertility treatment. Treatment options with recombinant gonadotrophins add more to knowledge on folliculogenesis and ovarian steroidogenesis. The role of recombinant luteinizing hormone is controversial undergoing ovarian stimulation and has been widely debated. Objective: To compare the effects of supplementation with recombinant luteinizing hormone (rLH) for controlled ovarian stimulation with recombinant follicle stimulating hormone (rFSH) in a protocol with GnRH-antagonist in cycles of IVF/ICSI. Methods: Case-control study with 113 patients attended at a university center in the city of Goiania, aged between 34-42 years, who were divided into two groups according to an ovarian stimulation scheme: Group I (n= 60): rFSH (control group) and Group II (n= 53): rFSH + rLH (treated group). These groups were comparable for age, BMI, duration of infertility, serum FSH, LH and estradiol. Numbers of oocytes collected and in metaphase II, fertilization rate, embryos rate and rates of chemical and clinical pregnancy were analyzed. Data analysis was conducted using the statistical software BioStat ® 5.3. Differences in proportions were assessed by chi-square test and means by Wilcoxon Mann- Whitney test. P < 0,05 was considered statistically significant. Results: The mean age of patients in Group I was 37.3±2.1 years and Group II 37.9±2.4 years (P > 0.05). The comparability of the other main characteristics (duration of infertility, BMI, FSH, LH and basal estradiol) were also observed between Groups I and II (P > 0.05). There was no significant difference between the two groups regarding: number of oocytes retrieved (Group I= 4.9 ± 2.1, Group II= 5.7 ± 2.6, P= 0.061), number of oocytes in metaphase II (Group I= 3.4 ± 1.6, Group II= 4.0 ± 1.9, P= 0.060), fertilization rate (Group I= 65.3%, Group II= 69.4 %, OR 1.20, 95% CI 0.85-1.70, P= 0.282), embryos rate (Group I= 85.4%, Group II= 88.5%, OR 1.31, 95% CI 0.73-2.36, P= 0.355), rate of chemical pregnancy (Group I= 20.0%, Group II= 24.5%; OR 1.30, 95% CI 0.53-3.16, P= 0.562) and clinical pregnancy rate (Group I= 20.0%, Group II= 22.6%, OR 1.17, 95% CI 0.47-2.89, P= 0.731). Conclusion: In this study it was concluded that supplementation with r-LH showed no benefit with respect to variables during controlled ovarian stimulation with GnRH antagonists. |
| eu_rights_str_mv | openAccess |
| format | doctoralThesis |
| id | UFG-2_75df057bcd8660bc9aa84e656c82e8ed |
| identifier_str_mv | MAIA, M. C. S. Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida. 2015. 101 f. Tese (Doutorado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2015. |
| instacron_str | UFG |
| institution | UFG |
| instname_str | Universidade Federal de Goiás (UFG) |
| language | por |
| network_acronym_str | UFG-2 |
| network_name_str | Repositório Institucional da UFG |
| oai_identifier_str | oai:repositorio.bc.ufg.br:tede/5408 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher.none.fl_str_mv | Universidade Federal de Goiás |
| reponame_str | Repositório Institucional da UFG |
| repository.mail.fl_str_mv | grt.bc@ufg.br |
| repository.name.fl_str_mv | Repositório Institucional da UFG - Universidade Federal de Goiás (UFG) |
| repository_id_str | oai:repositorio.bc.ufg.br:tede/1234 |
| rights_invalid_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| spelling | Approbato, Mário Silvahttp://lattes.cnpq.br/3408700658976397Approbato, Mário SilvaSanchez, Eliane Gouveia de MoraisSiriano, Liliane da RochaBarbosa, Maria AlvesGuimarães, Valeriana de Castrohttp://lattes.cnpq.br/8921727225719363Maia, Mônica Canêdo Silva2016-04-04T11:56:43Z2015-12-03MAIA, M. C. S. Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida. 2015. 101 f. Tese (Doutorado em Ciências da Saúde) - Universidade Federal de Goiás, Goiânia, 2015.http://repositorio.bc.ufg.br/tede/handle/tede/5408Controlled ovarian stimulation has become an integral part of infertility treatment. Treatment options with recombinant gonadotrophins add more to knowledge on folliculogenesis and ovarian steroidogenesis. The role of recombinant luteinizing hormone is controversial undergoing ovarian stimulation and has been widely debated. Objective: To compare the effects of supplementation with recombinant luteinizing hormone (rLH) for controlled ovarian stimulation with recombinant follicle stimulating hormone (rFSH) in a protocol with GnRH-antagonist in cycles of IVF/ICSI. Methods: Case-control study with 113 patients attended at a university center in the city of Goiania, aged between 34-42 years, who were divided into two groups according to an ovarian stimulation scheme: Group I (n= 60): rFSH (control group) and Group II (n= 53): rFSH + rLH (treated group). These groups were comparable for age, BMI, duration of infertility, serum FSH, LH and estradiol. Numbers of oocytes collected and in metaphase II, fertilization rate, embryos rate and rates of chemical and clinical pregnancy were analyzed. Data analysis was conducted using the statistical software BioStat ® 5.3. Differences in proportions were assessed by chi-square test and means by Wilcoxon Mann- Whitney test. P < 0,05 was considered statistically significant. Results: The mean age of patients in Group I was 37.3±2.1 years and Group II 37.9±2.4 years (P > 0.05). The comparability of the other main characteristics (duration of infertility, BMI, FSH, LH and basal estradiol) were also observed between Groups I and II (P > 0.05). There was no significant difference between the two groups regarding: number of oocytes retrieved (Group I= 4.9 ± 2.1, Group II= 5.7 ± 2.6, P= 0.061), number of oocytes in metaphase II (Group I= 3.4 ± 1.6, Group II= 4.0 ± 1.9, P= 0.060), fertilization rate (Group I= 65.3%, Group II= 69.4 %, OR 1.20, 95% CI 0.85-1.70, P= 0.282), embryos rate (Group I= 85.4%, Group II= 88.5%, OR 1.31, 95% CI 0.73-2.36, P= 0.355), rate of chemical pregnancy (Group I= 20.0%, Group II= 24.5%; OR 1.30, 95% CI 0.53-3.16, P= 0.562) and clinical pregnancy rate (Group I= 20.0%, Group II= 22.6%, OR 1.17, 95% CI 0.47-2.89, P= 0.731). Conclusion: In this study it was concluded that supplementation with r-LH showed no benefit with respect to variables during controlled ovarian stimulation with GnRH antagonists.A estimulação ovariana controlada tornou-se parte integrante no tratamento da infertilidade. As opções de tratamento com gonadotrofinas recombinantes adicionaram mais conhecimento da foliculogênese e esteroidogênese ovariana. O uso do hormônio luteinizante recombinante é controverso em pacientes que passam por estimulação ovariana e tem sido amplamente debatido. Objetivo: Comparar os efeitos da suplementação de LHr para a estimulação ovariana controlada com FSHr em um protocolo com antagonista de GnRH em ciclos de FIV/ICSI. Métodos: Estudo caso-controle com 113 pacientes atendidas em um centro universitário na cidade de Goiânia, idade entre 34 a 42 anos, as quais foram divididas em dois grupos de acordo com a estimulação ovariana: Grupo I (n= 60): FSHr (grupo controle) e Grupo II (n= 53): FSHr + LHr (grupo tratado). Estes grupos foram comparáveis para idade, IMC, duração da infertilidade, níveis séricos de FSH, LH e estradiol. Foram analisados número de ovócitos coletados e em metáfase II, taxa de fertilização, taxa de clivagem embrionária, taxas de gravidez química e clínica. A análise de dados foi realizada pelo programa estatístico Bioestat 5.3®. As diferenças de proporções foram avaliadas por teste de Qui-quadrado e as médias pelo teste Wilcoxon Mann-Whitney. p < 0,05 foi considerado estatisticamente significante. Resultados: A média de idade das pacientes do Grupo I foi 37,3 ± 2,1 anos e do Grupo II de 37,9 ± 2,4 anos (p > 0,05). A comparabilidade das outras principais características (duração da infertilidade, índice de massa corporal, FSH, LH e estradiol basal) foram também observadas entre os Grupos I e II (p > 0,05). Não houve diferença significativa entre os dois grupos em relação ao: número de ovócitos captados (Grupo I= 4,9 ± 2,1; Grupo II= 5,7 ± 2,6; p= 0,061), número de ovócitos em metáfase II (Grupo I= 3,4 ± 1,6; Grupo II= 4,0 ± 1,9; p= 0,060), taxa de fertilização (Grupo I= 65,3%; Grupo II= 69,4%; OR 1,20; IC 95% 0,85-1,70; p= 0,282), taxa de clivagem embrionária (Grupo I= 85,4%; Grupo II= 88,5%; OR 1,31; IC 95% 0,73-2,36; p= 0,355), taxa de gravidez química (Grupo I= 20,0%; Grupo II= 24,5%; OR 1,30; IC 95% 0,53-3,16; p= 0,562) e taxa de gravidez clínica (Grupo I= 20,0%; Grupo II= 22,6%, OR 1,17; IC 95% 0,47-2,89; p= 0,731). Conclusão: Neste estudo concluiu-se que a suplementação com LHr não demonstrou benefício em relação às variáveis analisadas durante a estimulação ovariana controlada com antagonistas de GnRH.application/pdfporUniversidade Federal de GoiásPrograma de Pós-graduação em Ciências da Saúde (FM)UFGBrasilFaculdade de Medicina - FM (RG)http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessEstimulação ovarianaFertilização in vitroHormônio luteinizante recombinanteSuplementação com LHOvarian stimulationIn vitro fertilizationRecombinant luteinizing hormoneSupplementation LHCIENCIAS DA SAUDE::MEDICINAUso do hormônio luteinizante recombinante em ciclos de fertilização assistidaUse of recombinant luteinizing hormone in assisted reproduction cyclesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesis-10068643126177453106006006001545772475950486338-969369452308786627reponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGLICENSElicense.txtlicense.txttext/plain; charset=utf-82165http://repositorio.bc.ufg.br/tede/bitstreams/28250bbb-3f61-445b-bd42-9c769c168e2c/downloadbd3efa91386c1718a7f26a329fdcb468MD51CC-LICENSElicense_urllicense_urltext/plain; charset=utf-849http://repositorio.bc.ufg.br/tede/bitstreams/32bd894b-1d4a-4bce-9317-720756b7fa7d/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-822064http://repositorio.bc.ufg.br/tede/bitstreams/f2adccdb-9a8c-47fa-ab15-418c3f5cc957/downloadef48816a10f2d45f2e2fee2f478e2fafMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-823148http://repositorio.bc.ufg.br/tede/bitstreams/98b32863-04be-4f0a-8a0d-f8723a2fda8c/download9da0b6dfac957114c6a7714714b86306MD54ORIGINALTese - Mônica Canêdo Silva Maia - 2015.pdfTese - Mônica Canêdo Silva Maia - 2015.pdfapplication/pdf2190840http://repositorio.bc.ufg.br/tede/bitstreams/c9b62c93-2fa0-458b-ab40-e60d2a7f7f0a/downloadb52ab9d3f319bc193309f78f9ef2e243MD55tede/54082016-04-04 08:56:43.627http://creativecommons.org/licenses/by-nc-nd/4.0/Acesso Abertoopen.accessoai:repositorio.bc.ufg.br:tede/5408http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttps://repositorio.bc.ufg.br/tedeserver/oai/requestgrt.bc@ufg.bropendoar:oai:repositorio.bc.ufg.br:tede/12342016-04-04T11:56:43Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)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 |
| spellingShingle | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida Maia, Mônica Canêdo Silva Estimulação ovariana Fertilização in vitro Hormônio luteinizante recombinante Suplementação com LH Ovarian stimulation In vitro fertilization Recombinant luteinizing hormone Supplementation LH CIENCIAS DA SAUDE::MEDICINA |
| status_str | publishedVersion |
| title | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| title_full | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| title_fullStr | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| title_full_unstemmed | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| title_short | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| title_sort | Uso do hormônio luteinizante recombinante em ciclos de fertilização assistida |
| topic | Estimulação ovariana Fertilização in vitro Hormônio luteinizante recombinante Suplementação com LH Ovarian stimulation In vitro fertilization Recombinant luteinizing hormone Supplementation LH CIENCIAS DA SAUDE::MEDICINA |
| url | http://repositorio.bc.ufg.br/tede/handle/tede/5408 |